Literature DB >> 21442797

Erratum to: Ungersma SE, Pacheco G, Ho C, Yee SF, Ross J, van Bruggen N, Peale FV Jr, Ross S, Carano RA. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med 2010;63:1637–1647.

Sharon E Ungersma1, Glenn Pacheco, Calvin Ho, Sharon Fong Yee, Jed Ross, Nicholas van Bruggen, Franklin V Peale, Sarajane Ross, Richard A D Carano.   

Abstract

Imaging of tumor microvasculature has become an important tool for studying angiogenesis and monitoring antiangiogenic therapies. Ultrasmall paramagnetic iron oxide contrast agents for indirect imaging of vasculature offer a method for quantitative measurements of vascular biomarkers such as vessel size index, blood volume, and vessel density (Q). Here, this technique is validated with direct comparisons to ex vivo micro-computed tomography angiography and histologic vessel measurements, showing significant correlations between in vivo vascular MRI measurements and ex vivo structural vessel measurements. The sensitivity of the MRI vascular parameters is also demonstrated, in combination with a multispectral analysis technique for segmenting tumor tissue to restrict the analysis to viable tumor tissue and exclude regions of necrosis. It is shown that this viable tumor segmentation increases sensitivity for detection of significant effects on blood volume and Q by two antiangiogenic therapeutics [anti-vascular endothelial growth factor (anti-VEGF) and anti-neuropilin-1] on an HM7 colorectal tumor model. Anti-vascular endothelial growth factor reduced blood volume by 36±3% (p<0.0001) and Q by 52±3% (p<0.0001) at 48 h post-treatment; the effects of anti-neuropilin-1 were roughly half as strong with a reduction in blood volume of 18±6% (p<0.05) and a reduction in Q of 33±5% (p<0.05) at 48 h post-treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21442797     DOI: 10.1002/mrm.22880

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  5 in total

1.  Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.

Authors:  L Heijmen; C J A Punt; E G W Ter Voert; L F de Geus-Oei; A Heerschap; J Bussink; C G J Sweep; V Zerbi; W J G Oyen; P N Span; O Boerman; H W M van Laarhoven
Journal:  Invest New Drugs       Date:  2013-01-17       Impact factor: 3.850

Review 2.  High-field small animal magnetic resonance oncology studies.

Authors:  Louisa Bokacheva; Ellen Ackerstaff; H Carl LeKaye; Kristen Zakian; Jason A Koutcher
Journal:  Phys Med Biol       Date:  2013-12-30       Impact factor: 3.609

3.  Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma.

Authors:  Hermann B Frieboes; Bryan R Smith; Zhihui Wang; Masakatsu Kotsuma; Ken Ito; Armin Day; Benjamin Cahill; Colin Flinders; Shannon M Mumenthaler; Parag Mallick; Eman Simbawa; A S Al-Fhaid; S R Mahmoud; Sanjiv S Gambhir; Vittorio Cristini
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

4.  Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.

Authors:  Shuohui Yang; Jiang Lin; Fang Lu; Zhihong Han; Caixia Fu; Hongchen Gu
Journal:  Contrast Media Mol Imaging       Date:  2017-06-21       Impact factor: 3.161

5.  Intravoxel Incoherent Motion Diffusion Weighted Magnetic Resonance Imaging for Differentiation Between Nasopharyngeal Carcinoma and Lymphoma at the Primary Site.

Authors:  Xiao-Ping Yu; Jing Hou; Fei-Ping Li; Hui Wang; Ping-Sheng Hu; Feng Bi; Wei Wang
Journal:  J Comput Assist Tomogr       Date:  2016 May-Jun       Impact factor: 1.826

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.